Mucosis Receives Financial Support from the Dutch Government for its SynGEM® Program
Biotechnology company Mucosis B.V. today announced that it has received an innovation credit line of up to €5 million fr…
Biotechnology company Mucosis B.V. today announced that it has received an innovation credit line of up to €5 million fr…
Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, today announced that it…
Mucosis B.V., the Dutch clinical-stage biotechnology company developing mucosal vaccines, today announced the appointmen…
Dutch vaccine development company Mucosis B.V. today announced Phase I clinical data providing proof-of-concept that Mim…
Dutch biotechnology company Mucosis B.V. today announced the publication in the peer-reviewed journal Vaccine of preclin…
Dutch biotechnology company Mucosis B.V. today announced that it has appointed professors Jiri Mestecky, M.D., Ph.D.; Wi…
Dutch biotechnology company Mucosis B.V. today announced the appointment of Thomas Johnston as Chief Business Officer. I…
Dutch biotechnology company Mucosis B.V. announced today that Dr. Barry Buckland was elected to its Supervisory Board. D…
Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the glo…
Dutch biotechnology company Mucosis B.V. announced today that John Lambert was elected as member and chair of its Superv…